What does the evidence say about Chicory Root Fiber Blood Glucose Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Chicory Root Fiber Blood Glucose Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Clinically, chRG-I was well-tolerated and slightly improved stool consistency compared to placebo. [Kerezoudi EN (2026); evidence level 4] - In an intestinal barrier challenge model, chRG-I fermentates (a pool of metabolites including SCFA and fragments of chRG-I) protected barrier integrity, modulated the cytokine milieu away from a predominantly pro-inflammatory response, as characterized by increased IL4 and IL22 and reduced IL9, IL17A, and IL21. [Kerezoudi EN (2026); evidence level 4] - Conclusion: Supplementation with a low dose of chRG-I is well-tolerated, beneficially modulates the gut microbiome - which can protect the intestinal barrier, and subtly enhances systemic immune readiness, suggesting that chRG-I may have benefits as a functional food ingredient. [Kerezoudi EN (2026); evidence level 4] - Background: Pectic rhamnogalacturonan-I (RG-I) is a dietary fiber that modulates the gut-immune axis. [Kerezoudi EN (2026); evidence level 4] - Interestingly, we previously found that short-term (3 weeks), daily intake of 30 g/day of dried chicory root fibers in individuals at risk of T2D rapidly modulated the gut microbiota by increasing relative levels ofspp. [Omary Lina (2025); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.